| abstract |
In compounds of formula (1.0.0) useful as inhibitors of PDE4 in the treatment of diseases regulated by activation and degranulation of eosinophils, especially asthma, chronic bronchitis and chronic obstructive pulmonary disease, j is 0 or 1 where j is 0 N is provided to be 2); k is 0 or 1; m is 1, 2 or 3; n is 1 or 2; W 1 and W 2 are -O-, -S (= 0) t- (where t is 0, 1 or 2), or -N (R 3 )-; Y is = C (R 1 a )-or-[N⇒ (O) k ]-(where k is 0 or 1); R 1 a is —H, —F, —Cl, —CN, —NO 2 , — (C 1 -C 4 ) alkyl,-(C 2 -C 4 ) alkynyl, fluorinated- (C 1 -C 3) alkyl, fluoro Chemistry - (C 1 -C 3) alkoxy, -OR 16 or -C (= O) NR 22 a R 22 b is a; R A and R B are -H, -F, -CF 3 ,-(C 1 -C 4 ) alkyl,-(C 3 -C 7 ) cycloalkyl, phenyl, or benzyl substituted with 0 to 3 R 10 Or; r and s are provided from 0 to 4, provided that when R + s is at least 1 and less than 5, R A and R B together form a spiro residue of formula (1.0.5); X is -CH 2- , -CHF, -CF 2 , -NR 15- , -O- or -S (= 0) t- (where t is 0, 1); R C and R D are the same as defined above for R A and R B , except that one of them must be -H; R 1 and R 2 are —H, —F, —Cl, —CN, —NO 2 , — (C 1 -C 4 ) alkyl, — (C 2 -C 4 ) alkynyl, fluorinated- (C 1 -C 3 ) alkyl, -OR 16 or -C (= 0) NR 22 a R 22 b ; R 3 is —H, — (C 1 -C 3 ) alkyl, phenyl, benzyl or —OR 16 ; R 4 , R 5 and R 6 , D, J 1 and J 2 are defined herein. |